5-ARI COMPARISON
Finasteride vs Dutasteride for BPH: Two 5-ARIs, Different Pharmacology
Finasteride and dutasteride are both 5-alpha-reductase inhibitors used for BPH, but they are not identical. Finasteride primarily inhibits type II 5-alpha-reductase, while dutasteride inhibits type I and II, and dutasteride has a much longer half-life. Both are slower-onset prostate-directed treatments, and both can cause sexual adverse effects. The decision should focus on prostate findings, treatment goals, side-effect tolerance and the implications of a longer-persisting drug.
Decision snapshot
| Search intent | finasteride vs dutasteride for BPH |
|---|---|
| Main concern | Comparing the two prostate-directed 5-alpha-reductase inhibitors |
| What this page can do | Explain evidence, mechanism, trade-offs and questions to discuss with a clinician. |
| What this page cannot do | Diagnose the cause, choose a prescription, or tell you to start, stop or switch treatment. |
Same class does not mean same pharmacology
The AUA guideline evidence base describes an important mechanistic distinction: finasteride targets type II 5-alpha-reductase while dutasteride targets both type I and II. Dutasteride also persists in the body much longer. Those differences may matter for adherence, switching and how long effects or adverse effects can persist after a change.
What they have in common
Both drugs are intended as prostate-directed strategies rather than rapid symptom-relief drugs. They are most relevant when prostate enlargement is part of the treatment rationale. Both can improve urinary symptom scores over time and reduce prostate-related progression risk in appropriate patients. Both also require attention to sexual adverse effects and PSA interpretation.
Why direct superiority claims are usually unhelpful
AUA evidence has not supported a simple claim that one is universally clinically superior for every man. A direct comparison study cited in earlier guidelines found no meaningful differences in several core outcomes over 12 months. The practical decision may therefore rest more on prior response, tolerance, pharmacokinetics, clinician preference, formulary access and the exact treatment goal.
Direct comparison
| Factor | Finasteride | Dutasteride |
|---|---|---|
| Drug class | 5-alpha-reductase inhibitor | 5-alpha-reductase inhibitor |
| Enzyme inhibition | Primarily type II | Type I and II |
| Half-life | Hours | Weeks |
| Onset | Gradual | Gradual |
| Sexual adverse effects | Can occur | Can occur |
| PSA interpretation | Affected | Affected |
This table is an educational summary. Individual suitability depends on diagnosis, prostate findings, blood pressure, cardiovascular history, other medicines, treatment goals and side-effect tolerance.
How to use this page as a decision tool
This page is designed for someone who is already close to a treatment decision. Instead of giving a generic overview of enlarged prostate, it focuses on the exact trade-off behind the search: comparing the two prostate-directed 5-alpha-reductase inhibitors. Write down the symptom that is driving the search, what changed after treatment, and what outcome matters most over the next three to six months. A weak stream, frequent urgency, repeated nighttime trips and sexual side effects are not interchangeable problems, even when they appear under the same BPH diagnosis.
What should be measured before a switch or escalation?
A useful follow-up compares the same outcomes before and after treatment. Track stream strength, hesitation before urine starts, straining, stop-start flow, the sense of incomplete emptying, daytime frequency, urgency and nighttime bathroom trips. If sexual function is part of the decision, track desire, erection quality and ejaculation separately. If dizziness or blood-pressure symptoms are involved, record when they happen and whether they are linked to standing up, exercise, alcohol or other medicines.
Objective evaluation can be just as important as the symptom diary. Depending on the situation, a clinician may use urinalysis, PSA-related testing, post-void residual, uroflowmetry, imaging, cystoscopy or urodynamic testing. The point is not to order every test. It is to avoid repeatedly changing medication when the underlying problem has not been defined well enough.
Red flags that should override the comparison
Search intent stops mattering when urgent symptoms appear. Inability to urinate, blood in the urine, urinary symptoms with fever or chills, or severe lower-abdominal or urinary-tract pain require prompt medical assessment. Recurrent urinary infections, worsening kidney function, repeated retention episodes or a persistently large post-void residual may also change the treatment conversation from “which pill?” to whether further testing or a procedure is appropriate.
For non-urgent problems, the goal is shared decision-making rather than internet prescribing. A well-structured comparison can help you understand mechanisms, timelines and trade-offs. It cannot determine whether the prostate is actually the cause of the symptoms, whether a drug is safe with your other medicines, or whether the benefits outweigh the risks in your specific medical history.
Questions worth taking to a clinician
- Is BPH definitely the main cause of my symptoms, or should another urinary problem be ruled out?
- Is my prostate size or progression risk important to this treatment choice?
- What benefit should I reasonably expect, and over what timeline?
- Which side effects are most relevant to my priorities?
- Could any prescription, over-the-counter medicine or supplement be contributing to the problem?
- If this treatment is not enough, what is the next logical mechanism to consider?
- At what point would testing or a procedure be more useful than another medication change?
Related high-intent guides
Match the information to your symptom pattern
The assessment route is designed to organize the concern behind this search. It is educational, not a diagnosis, and it should not replace medical evaluation.
Medication Concerned AssessmentFrequently asked questions
Is dutasteride stronger than finasteride?
Dutasteride suppresses more 5-alpha-reductase activity systemically, but “stronger” is not the same as proven better for every clinical outcome.
Which works faster for BPH?
Both are slow-onset 5-ARI treatments. Neither should be expected to behave like a rapid-relief alpha blocker.
Which has more sexual side effects?
Both labels include sexual adverse effects. Individual tolerance varies, and cross-trial percentages should not be treated as a perfect head-to-head comparison.
Can I switch from finasteride to dutasteride directly?
Switching should be clinician-directed because the drugs have different pharmacokinetics and the reason for switching matters.
Do both affect PSA?
Yes. Clinicians interpreting PSA need to know about 5-ARI therapy.
Does a weak stream always mean BPH?
No. BPH is common, but similar urinary symptoms can come from bladder problems, infection, prostatitis, urethral narrowing, neurologic disease, medicines and other causes. Persistent or worsening symptoms deserve clinical evaluation.
When is urinary trouble urgent?
Seek prompt medical care if you cannot urinate at all, have blood in the urine, have urinary symptoms with fever or chills, or have severe lower-abdominal or urinary-tract pain.
Can I change a prescription based on an online article?
No. Do not start, stop, restart, double, split or switch a prescription based only on online information. Use the article to prepare questions for the prescriber who knows your diagnosis, other medicines and risk factors.
Can supplements replace prescription BPH treatment?
Do not assume equivalence. Evidence varies by supplement, and supplement quality can vary. A supplement should not be treated as a prescription substitute without discussing the reason for treatment and the evidence with a clinician.
Can BPH treatment affect sexual function?
Yes. Depending on the medicine, changes can involve libido, erections, ejaculation or semen volume. The pattern differs by drug class and person, so sexual priorities belong in shared decision-making.
Does prostate size always match symptom severity?
No. A larger prostate can cause modest symptoms while a smaller enlargement can interfere substantially with urination. Symptoms, examination findings and objective testing all help define the problem.
What tests might be used when symptoms persist?
Depending on the situation, evaluation can include history, physical examination, urinalysis, PSA-related testing, post-void residual, uroflowmetry, imaging, cystoscopy or urodynamic testing.
Sources used for this page
- FDA: AVODART (dutasteride) prescribing information
- NIDDK: Enlarged Prostate (BPH)
- AUA: BPH guideline listing (2026)
Evidence summaries are deliberately conservative. Medical guidance changes, and individual treatment decisions require a qualified clinician.